Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients.
about
Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitroCombinations of 3'-azido-3'-deoxythymidine (zidovudine) and phosphonoformate (foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replication in vitroComparative study of the anti-human cytomegalovirus activities and toxicities of a tetrahydrofuran phosphonate analogue of guanosine and cidofovirCurrent status of renal transplantation.New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipientsLiposomal encapsulation of foscarnet protects against hypocalcemia induced by free foscarnet.Age-related differences in pharmacokinetics of phosphonoformate in cats.Increased efficacy of phosphonoformate and phosphonoacetate inhibition of herpes simplex virus type 2 replication by encapsulation in liposomes.Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome.Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis.Infections in solid-organ transplant recipientsPharmacokinetics of foscarnet after twice-daily administrations for treatment of cytomegalovirus disease in AIDS patients.Antiviral therapy: current concepts and practicesOral activity of a methylenecyclopropane analog, cyclopropavir, in animal models for cytomegalovirus infections.Herpesvirus and enteric viral infections in bone marrow transplantation: clinical presentations, pathogenesis, and therapeutic strategies.Human cytomegalovirus infection.Fiberoptic bronchoscopy for diagnosis of opportunistic pulmonary infections after bone marrow transplantation.Pharmacokinetics of foscarnet and distribution to cerebrospinal fluid after intravenous infusion in patients with human immunodeficiency virus infection.Antimicrobial strategies in the care of organ transplant recipientsGanciclovir-resistant cytomegalovirus clinical isolates: mode of resistance to ganciclovir.Foscarnet for treatment of cytomegalovirus infections in bone marrow transplant recipients.Allogeneic bone marrow transplantation for hematological malignancies--controversies and recent advances.Neurologic sequelae associated with foscarnet therapy.Use of phosphonoformic acid to induce phosphaturia in chronic renal failure in rats.G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV.Evaluation by immune scanning electron microscopy of foscarnet treatment of cytomegalovirus infection in patients with renal transplants.Clinical use of immunohistopathologic methods for the diagnosis of cytomegalovirus hepatitis in human liver allograft biopsy specimens.Multiplex CRISPR/Cas9 system impairs HCMV replication by excising an essential viral gene.
P2860
Q28330357-DA7207AE-09D4-48DE-A3F4-FA638D822285Q28342758-26F10A6F-9BBA-4D54-B4B4-08AF1C1DFBB3Q28343171-0541C349-DF8B-4A0E-9F27-F10D4F1521BCQ33558294-FDB9B2BF-58E2-49F2-9B7E-7923F37364B1Q33812425-9D334EC7-263D-45BA-A00D-6A83C0E18960Q35118174-D60A95E0-8340-4942-9A54-D4C2B689D713Q35254452-2D97570C-AAF6-4C9E-BA86-1D4EED751B47Q35309077-A1FB359E-F481-42AE-85EE-E3EE281F8956Q35333512-D741865B-B40A-4888-93EB-A61B3F4EB37FQ35333643-8BF08CF1-F50E-430E-997A-51729CC3ACF1Q35376486-FE7DFB01-94F2-4F7A-8D22-A5EA58C271EDQ35896783-FE9BC328-3E37-45DE-AB49-B41F0B13CC1AQ36070394-180B7D08-5BE3-4291-843B-8C8184E9D246Q37624896-E86C90F5-B944-4F81-A991-AD1199A2B5EEQ37901418-4DAAFD98-AEE1-4117-91E3-129CA1481918Q38284547-E764140C-8B69-4097-A508-F97E31FC47AAQ38727381-509ADD16-C056-4BEA-850A-1B5B3EF7971FQ39833019-94EB9635-9A2F-417F-8E65-F7DADD0D546EQ39865375-7B7ADB00-2F28-428B-8C8E-A8B888623C5CQ40087885-C7B36909-E7BC-4A52-9B3A-E2D85A142271Q40741038-0F0BC2B2-7595-41A9-B6E1-DA0BD4A7AC84Q41668011-1553BCB0-60A8-42E9-8A39-9E7F70A9A728Q42280002-11323384-5CC8-4A7E-9884-C3E25D133EE5Q42552111-49D02CEC-922B-437C-A7BB-994EFF8B3125Q44499728-6404F5C8-6778-4BBB-A46F-93D545D0BD7AQ44662429-F09B7B62-0E0E-40B8-B01A-7EE88242609AQ44985842-E4F013EC-5DB0-4B8B-8D54-DF9588C1DD29Q49980151-266BC742-77FA-4092-8B2E-F435D43D1D6F
P2860
Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients.
description
1986 nî lūn-bûn
@nan
1986年の論文
@ja
1986年論文
@yue
1986年論文
@zh-hant
1986年論文
@zh-hk
1986年論文
@zh-mo
1986年論文
@zh-tw
1986年论文
@wuu
1986年论文
@zh
1986年论文
@zh-cn
name
Pharmacokinetics, safety and p ...... d renal transplant recipients.
@en
type
label
Pharmacokinetics, safety and p ...... d renal transplant recipients.
@en
prefLabel
Pharmacokinetics, safety and p ...... d renal transplant recipients.
@en
P2093
P356
P1476
Pharmacokinetics, safety and p ...... d renal transplant recipients.
@en
P2093
Klintmalm G
Lernestedt JO
Lönnqvist B
P304
P356
10.1093/JAC/17.3.373
P407
P577
1986-03-01T00:00:00Z